A real‐life experience of long‐term use of pilocarpine in irradiated head and neck cancer patients
Oral Diseases · 2024
DOI: 10.1111/odi.14905 ↗At a glance
Beobachtungsstudie in Oral Diseases, 2024. Written by Rungarun Kittichet and 3 co-authors. Institution: Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Prince of Songkhla University, Songkhla, Thailand. Major MEDLINE topics: Head and Neck Neoplasms, Pilocarpine, Xerostomia, Radiation Injuries. Cited 2 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Topics: Onkologische Pflege
Abstract (original language)
Aims
To assess long‐term efficacy and side effects of pilocarpine on irradiated head and neck cancer (HNC) patients in both for prevention and treatment of radiation‐induced xerostomia (RIX).
Methods
Retrospective observational study was conducted. Eligibility criteria included irradiated HNC patients who received pilocarpine at least 12 weeks either for prevention (group A) or for treatment (group B) of RIX. We collected the documented Late Effect Normal Tissue Task Force‐Subjective, Objective, Management, Analytics subjective/objective grades of RIX before (only group B) and the latest visit for pilocarpine prescription, dosage, side effects, duration of treatment, and the cause of discontinuation.
Results
Between December 2007 and June 2022, 182 patients were enrolled including 95 patients (52%) in group A and 87 patients (48%) in group B. Group A patients reported grades 1, 2, 3, and 4 objective RIX in 0%, 7%, 93%, and 0%. Grade 1, 2, and 3 subjective RIX were 57%, 28%, and 15%. All patients in group B had grade 3 both objective/subjective RIX. The overall improvement of objective/subjective RIX was found in 40%/83%. Discontinuation was found in 51% of patients due to tolerable symptoms or deterioration of the patient's status.
Conclusions
Based on this retrospective analysis, long‐term use of pilocarpine in irradiated HNC appears feasible for both prevention and treatment of RIX.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Prince of Songkhla University, Songkhla, Thailand.
- Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- Northern Thai Research Group of Radiation Oncology (NTRG-RO), Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
ORCID profiles: Imjai Chitapanarux
Cite
APA
Kittichet, R., Chitapanarux, I., Kittidachanan, K., & Sripan, P. (2024). A real‐life experience of long‐term use of pilocarpine in irradiated head and neck cancer patients. Oral Diseases. https://doi.org/10.1111/odi.14905
Vancouver
Kittichet R, Chitapanarux I, Kittidachanan K, Sripan P. A real‐life experience of long‐term use of pilocarpine in irradiated head and neck cancer patients. Oral Diseases. 2024. doi:10.1111/odi.14905
BibTeX
@article{Kittichet2024,
author = {Kittichet, Rungarun and Chitapanarux, Imjai and Kittidachanan, Kittikun and Sripan, Patumrat},
title = {A real‐life experience of long‐term use of pilocarpine in irradiated head and neck cancer patients},
journal = {Oral Diseases},
year = {2024},
doi = {10.1111/odi.14905}
}
EUVIMED